What to know about the gBETA Medtech Pitch Night event:

  • gBETA Medtech, a gener8tor program, will be holding a virtual Pitch Night event for its Spring 2021 cohort on Monday, June 7, 2021 from 4:00-6:00 p.m.
  • The event is free and open to the public
  • You can register here
  • Each Spring 2021 cohort company will give a five-minute pitch followed by Q&A and a networking session

Check out the full lineup of the gBETA Medtech Spring 2021 cohort below.

tech.mn-the-circuit-subscribe

Anna Lisa Somera, Co-Founder and CEO | [email protected] | www.rhaeos.com

Rhaeos’ FlowSense noninvasive wearable skin patch initially targets hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid. Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. FlowSense is a thermal flow sensor that is mounted on a patient’s skin overlying the shunt to detect shunt flow in minutes, bedside, without capital equipment. Rhaeos has raised $2.3M in financing, received FDA breakthrough designation, published clinical data in Science and Nature family journals, and is on track for initial market entry in Q1 2022.

 

Mark Byrne, President and CEO | [email protected]

OpalGenix’s patented genotype-based opioid risk prediction and clinical decision support platform, GPS-Opioid, empowers clinicians to personalize therapy for patients who require opioids for pain. In the U.S., 30 million adult and pediatric patients are given opioids for pain relief after surgical procedures annually. Each person responds differently to opioids based on genetics and clinical factors, making medication management challenging for physicians. GPS-Opioid assesses each patient’s risk of opioid adverse effects and personalizes opioid selection and dosing to maximize pain relief and minimize opioid-related safety risks and costs. OpalGenix has recruited an accomplished startup CEO, completed pediatric clinical studies, obtained USPTO and European patent claims, and received notice of intent to fund an NIH STTR grant proposal.

image.png

Max Bock-Aronson, Founder and CEO | [email protected] | www.breathe99.com

Breathe99’s B2 Mask offers industrial-grade protection in a comfortable,  lifestyle design ideal for everyday use. Infectious diseases, wildfire smoke and ambient air pollution result in >8M preventable deaths globally. However, there is still a need to improve the aesthetics, comfort, utility and protective capabilities of masks. The B2 Mask’s patent-pending design offers an ergonomic face seal, can be personalized with stylish fabric overlays, and uses high-efficiency filters to provide unparalleled protection. Breathe99’s B2 Mask, recognized as one of TIME’s Best Inventions of 2020, has been shipped to over 24,000 happy customers globally, representing $1.5M+ in revenue since April 2020.

Jinesh Patel, Co-Founder and CEO | [email protected] | www.UptimeHealth.com

UptimeHealth’s online platform simplifies medical equipment service events, purchases and compliance practices through automation and predictive analytics. Management of medical equipment is currently paper-based and inefficient. UptimeHealth’s software allows medical equipment owners and suppliers to manage compliance, gain access to actionable data to increase operational efficiencies, and tap into the largest network of qualified biomedical technicians to support their devices. UptimeHealth has 150+ facilities, 1,300+ technicians on the platform, and generated $150k+ in revenue since launching in 2018.

Dr. Ian Makey, Co-Founder | [email protected]

Xtraction Corp’s patented sleeve technology advances minimally invasive surgeries by making specimen and organ retrieval easy and efficient. As minimally invasive surgeries advance towards smaller incisions, removal of specimens and organs becomes more challenging. Xtraction Corp’s novel technology allows surgeons to remove large specimens or organs out of small incisions, reducing procedure time and improving the recovery of patients.  Xtraction Corp is targeting the 1.8 million US and 6 million World Wide minimally invasive surgical procedures requiring specimen retrieval. Xtraction Corp has patented the technology, designed and developed prototypes, and tested the device in simulated surgical environments.